Close
CDMO Safety Testing 2026
Novotech

Qualicaps to invest $26m for Whitsett facility expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Holista Launches Collagen Production JV With SCC in Collie

Holista Colltech Limited has entered into a binding joint...

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...
- Advertisement -

Pharmaceutical manufacturer Qualicaps will invest $26m to expand its facility in Whitsett, North Carolina in the US.

Under the expansion plans, the firm will also add additional 100,000 ft² building space. The project will be funded by the Guilford County Board of Commissioners and the State of North Carolina, which are providing economic development incentive grants of $272,805 and $235,000 respectively.

Greensboro Economic Development Alliance president Dan Lynch said Qualicaps decision to expand their manufacturing operations validates the firm’s industry cluster strategy.

“Qualicaps represents two of our five clusters; life science and innovative manufacturing. By expanding in Guilford County they are able to benefit from our skilled workforce and leverage comprehensive training programs through GTCC,” Lynch added.

Qualicaps is a wholly owned subsidiary of Qualicaps Group, which is a manufacturer and supplier of two-piece medical and nutrition grade gelatin capsules.

 

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Holista Launches Collagen Production JV With SCC in Collie

Holista Colltech Limited has entered into a binding joint...

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »